Published in final edited form as:

J Gastrointest Surg. 2017 February ; 21(2): 352–362. doi:10.1007/s11605-016-3262-4.

Minimally Invasive Resection of Adrenocortical Carcinoma: A Multi-Institutional Study of 201 Patients

Christina W. Lee, MD¹, Ahmed I. Salem, MD¹, David F. Schneider, MD, MS¹, Glen E. Levenson, PhD¹, Thuy B. Tran, MD², George A. Poultsides, MD², Lauren M. Postlewait, MD³, Shishir K. Maithel, MD³, Tracy S. Wang, MD, MPH⁴, Ioannis Hatzaras, MD, MPH⁵, Rivka Shenoy, MD⁵, John E. Phay, MD⁶, Lawrence Shirley, MD⁶, Ryan C. Fields, MD⁷, Linda X. Jin, MD⁷, Timothy M. Pawlik, MD, MPH, PhD⁸, Jason D. Prescott, MD, PhD⁸, Jason K. Sicklick, MD⁹, Shady Gad, MD⁹, Adam C. Yopp, MD¹⁰, John C. Mansour, MD¹⁰, Quan-Yang Duh, MD¹¹, Natalie Seiser, MD, PhD¹¹, Carmen C. Solorzano, MD¹², Colleen M. Kiernan, MD¹², Konstantinos I. Votanopoulos, MD¹³, Edward A. Levine, MD¹³, and Sharon M. Weber, MD¹

¹ Department of Surgery, University Of Wisconsin School Of Medicine and Public Health - Madison, WI USA

² Department of Surgery, Stanford University - Palo Alto, CA USA

³ Department of Surgery, Emory University School of Medicine - Atlanta, GA USA

⁴ Department of Surgery, Medical College Of Wisconsin - Milwaukee, WI USA

⁵ Department of Surgery, New York University School of Medicine - New York, NY USA

⁶ Department of Surgery, Ohio State University - Columbus, OH USA

⁷ Department of Surgery, Washington University - St. Louis, MO USA

⁸ Department of Surgery, Johns Hopkins University School of Medicine - Baltimore, MD USA

⁹ Department of Surgery, University Of California - San Diego - San Diego, CA USA

¹⁰ Department of Surgery, University Of Texas Southwestern Medical Center - Dallas, TX USA

¹¹ Department of Surgery, University Of California - San Francisco - San Francisco, CA USA

¹² Department of Surgery, Vanderbilt University Medical Center - Nashville, TN USA

¹³ Department of Surgery, Wake Forest University School of Medicine - Winston-Salem, NC USA

Abstract

Correspondence: Sharon Weber, MD, University of Wisconsin School of Medicine and Public Health, H4/730 Clinical Science Center, Madison, WI 53792, (608) 262-2025, webers@surgery.wisc.edu.

Disclosures and Funding Sources: None.

Presentations: Podium presentation at the 2016 Academic Surgical Congress, February 3, 2016, Jacksonville, FL, USA

Author Contribution: Each author listed in the following manuscript contributed significantly to the concept and/or design of this work in the form of data acquisition, analysis and interpretation of results. Each author was involved in the drafting or revision of the intellectual content included in this manuscript and provided final approval of the current version. All authors agree to be accountable for the following work.

Background and Objectives—Minimally invasive surgery for adrenocortical carcinoma (ACC) is controversial. We sought to evaluate the perioperative and long-term outcomes following minimally invasive (MIS) and open resection (OA) of ACC in patients treated with curative intent surgery.

Methods—Retrospective data from patients who underwent adrenalectomy for primary ACC at 13 tertiary care cancer centers were analyzed, including demographics, clinicopathological, and operative outcomes. Outcomes following MIS were compared to OA.

Results—A total of 201 patients were evaluated including 47 MIS and 154 OA. There was no difference in utilization of MIS approach among institutions ($p=0.24$) or 30-day morbidity (29.3%, MIS versus 30.9%, OA, $p=0.839$). The only preoperatively determined predictor for MIS was smaller tumor size ($p<0.001$). There was no difference in rates of intraoperative tumor rupture ($p=0.612$) or R0 resection ($p=0.953$). Only EBL ($p=0.038$) and T stage ($p=0.045$) were independent prognostic indicators of overall survival after adjusting for significant factors. The surgical approach was not associated with overall or disease-free survival.

Conclusion—MIS adrenalectomy may be utilized for preoperatively determined ACC ≤ 10.0 cm, however OA should be utilized for adrenal masses with either preoperative or intraoperative evidence of local invasion or enlarged lymph nodes, regardless of size.

Keywords

Adrenocortical carcinoma; minimally-invasive surgery; survival; disease free survival; surgical approach

Introduction

Minimally invasive adrenalectomy (MIS) for primary adrenocortical carcinoma (ACC) remains a highly controversial topic despite the widespread acceptance of minimally invasive techniques among surgeons. The laparoscopic approach to adrenalectomy was first introduced in 1992 and has since been adopted as the preferred approach for resection of benign, functioning and non-functioning adrenal masses [1]. A greater number of published series revealing comparable short-term outcomes between MIS and open adrenalectomy (OA) have resulted in increased enthusiasm for MIS for adrenal malignancies, however these were hindered by small case series and variable duration of follow-up [2-6]. Despite the demonstrated safety and efficacy of MIS among small to medium sized, benign lesions (≤ 6 cm), OA remains the procedure of choice for ACC adrenalectomy, which allows for consistent and complete *en bloc* resection [2-6].

The two largest comparative series to date of MIS vs. included 46 laparoscopic cases from the University of Michigan, and 30 laparoscopic cases from the Italian Multi-institutional Study [4,7]. There were no differences in overall (OS) and disease-free survival (DFS) between groups in the Italian study, whereas the University of Michigan concluded OA was superior to the laparoscopic approach due to significantly different positive resection margins, incidence of tumor spillage, improved overall survival among stage II patients, and shorter time to recurrence [4,7]. The current study includes a large number of MIS adrenalectomies compared to OA.

ACC is a rare and aggressive malignancy afflicting approximately 2 patients per million per year, accounting for 0.2% of cancer-related mortality, with 5-year OS rates of 13% – 58% following resection [8-12]. Difficulty in treating most patients is attributed to locally advanced or metastatic disease at the time of presentation. In light of evidence demonstrating chemotherapy and radiation in ACC are largely ineffective, accomplishing a complete oncologic resection (R0) remains the most critical component to curative intent therapy, offering the only opportunity for long-term cure [8,11]. The early evidence on MIS versus OA offer conflicting outcomes however, a growing body of evidence reveal comparable short-term outcomes in carefully selected cases of early ACC, while abiding by the principles of oncological resection when performed at high volume centers. [2,5,7,9,13-15]. Anecdotal advantages of MIS for ACC include decreased post-operative pain, shorter length of stay, quicker rehabilitation, and fewer complications [6,16]. MIS has also been correlated with earlier recurrence rates, increased the risk of tumor spillage, or positive margins [7,13]. As a result, the current guidelines per the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) for resection of ACC dictate the standard treatment should be open surgery with the caveat that if malignancy is unknown preoperatively or if the MIS approach is initiated for suspected early stage disease, a low threshold for conversion is strongly recommended when there is evidence of invasion, adhesion or enlarged lymph nodes are seen, as the ideal treatment includes *en bloc* resection of any involved structures and regional lymphadenectomy [17].

In this study, we evaluated the oncologic and long-term survival outcomes of patients treated with MIS or OA in a multi-institutional collaboration among expert academic referral centers in the United States, drawing one of the largest numbers of MIS adrenalectomies reported to date.

Methods

Patients and Data Collection

Demographic, clinicopathological and perioperative data for all patients who underwent initial curative intent surgery for a diagnosis of adrenocortical carcinoma were collected between, 1994 to 2014. Patients were identified from one of 13 participating institutions in the United States Adrenocortical Carcinoma Group, including the University of Wisconsin, Johns Hopkins Hospital, Stanford University, Vanderbilt University, Emory University, Wake Forest University, Washington University in St. Louis, The Ohio State University, University of California San Francisco, Medical College of Wisconsin, University of Texas Southwestern Medical Center, and New York University. This study included both pediatric and adult populations. Patients diagnosed with metastatic disease and those who underwent re-operation for ACC were excluded from the study. All patient data was collected retrospectively from medical charts. Institutional review board approval was obtained at each participating institution.

Specific demographic, perioperative, and clinicopathological data included age, gender, ASA class, functional tumor status, laterality, EBL, preoperative tumor size, lymph node status, T stage, receipt of neoadjuvant and adjuvant therapies, capsular invasion, lymphatic and venous invasion and resection margin status. For T stage, two categories were created:

1) lower stage tumors (T1 and T2) and 2) higher stage tumors (T3 and T4). Perioperative complication data were also compared between groups, including in-hospital mortality, mortality within 30 days of operation, any complication within 30 days of operation, Clavien grade, occurrence of abdominal abscess, pancreatic leak, pulmonary embolism, intraoperative tumor rupture, postoperative adrenal insufficiency, reoperation, and readmission. For Clavien grade, two categories were created to define low grades of complications (grades I and II), and high grades of complications (III, IV and V). The surgical approach was reported as open or MIS. MIS included laparoscopic, hand-assisted, robotic and retroperitoneoscopic approaches to surgery. Open surgery was described as either abdominal, posterior, or thoracoabdominal. Readmission was defined as occurring within 90 days of operation. Disease recurrence was defined as biopsy-proven ACC or imaging reports consistent with or highly suggestive of tumor recurrence.

Predictors of Resection Margin Status

In order to identify factors with potential impact on resection margin status, the surgical approach, pre-operative tumor size, age, gender, and BMI were selected as the pre-operative factors available for univariable and logistic regression analyses. Three additional patient variables, the surgical era, tumor size category, and size-approach, were constructed to account for the potential influences of time throughout the course of the study, and the potential relationship between tumor size and surgical approach on resection margin status. The surgical era was defined as either early, the period between 1994 to 2005, or late, the period from 2006 to 2014. The tumor size overlap was defined as the range of tumor sizes in which both MIS and OA procedures were performed, and only these cases were used for this analysis. This range was then subdivided into 3 smaller categories to create the tumor size category variable. Tumor size categories were defined as 1 (3.7 - 7.0 cm), 2 (7.1 - 10.0 cm), or 3 (10.1 - 16 cm). The “size-approach” was a combined variable of the tumor size category in association with the surgical approach used (MIS or OA). This variable described the size of the tumor and whether an MIS or open approach to surgery was undertaken. For example, a tumor classified as “2-MIS” is one in which its size was between 7.1 - 10.0 cm and was resected by an MIS approach.

Prognostic Indicators of Overall and Disease-Free Survival

Overall (OS) and disease-free survival (DFS) times were computed for all patients starting from the date of operation. DFS was defined as the duration from the time of initial operation to the first documentation of disease recurrence.

Statistical Analyses

Demographic, clinicopathological, and perioperative patient data were stratified according to operative approach (MIS versus OA). This analysis was conducted under an intention to treat analysis, such that the MIS group were analysed with the patients that were converted to open surgery. Two additional subgroup analyses were conducted. One analysis evaluated patients within the MIS group alone in order to isolate potential predictors of conversion. Patients who underwent an MIS approach with subsequent conversion to open were compared to patients who underwent a non-converted MIS approach. A second comparison of non-converted MIS cases versus OA was also conducted.

Variables with potential correlations were analyzed by the Pearson product-moment correlation coefficient in order to identify the degree of linear dependence between two variables to avoid potential confounding. The variables EBL and operative transfusion were statistically correlated ($R>0.4$), therefore only EBL was included in univariable and multivariable analyses. Other variables with possible collinear relationships included tumor size with EBL, and tumor size with T stage, neither of which were correlated. Potential differences between groups were evaluated by χ^2 analyses and Student's t test where appropriate. Continuous data were reported as medians with ranges. Among the factors that satisfied the inclusion criteria for multivariable analysis, functional tumor status and venous invasion were excluded on the basis of significant missing data (75.0% missing), which presented a significant risk of unreliable estimates.

In the analysis of factors influencing resection margin status, all patients under tumor size category 3 (tumor size range: 10.1 cm – 16.0 cm, category 3-MIS and category 3-OA) were excluded due to the small number of patients in the 3-MIS group ($n=2$). Among the pre-operative factors available for analysis, the surgical approach, pre-operative tumor size, tumor size category, size-approach, age, gender, BMI and surgical era were included in univariable analysis. In multivariable logistic regression, factors with $p<0.1$ on univariable analyses were included in the model in addition to the size-approach variable.

In survival analyses, patient demographic, perioperative, and clinicopathological data were evaluated for differences between the MIS and open surgery groups using χ^2 and Student's t tests. Factors with $p<0.1$ were assessed for predictive capacity for OS and DFS in univariable and multivariable analyses via a Cox proportional hazards model. Overall and disease-free survival was estimated for each group using the methods of Kaplan and Meier. Additionally, propensity score analysis was utilized in order to adjust for pre-operative factors thought to impact the choice of surgical approach on OS and DFS. All preoperative factors satisfying $p<0.2$ in logistic regression analyses were included in the propensity score as follows: $PS = -3.142 + (0.148 \times \text{Era}) - (0.004 \times \text{Age}) - (0.485 \times \text{Functional tumor status}) + (1.234 \times \text{Gender}) + (0.513 \times \text{Tumor size})$. One-to-one matching was not possible due to a high degree of missing data, rather the propensity score was constructed and included with the surgical approach in an adjusted Cox proportional hazards model for OS and DFS. All statistical tests were two-sided and statistical significance was denoted by $p<0.05$. Statistical analyses were performed using SPSS software (version 23.0, IBM SPSS, Chicago, IL).

Results

Demographic and Clinicopathological Characteristics

The original study cohort consisted of 265 cases of adrenalectomy for ACC. Twelve cases were excluded due to unreported approach to surgery, and 52 cases were excluded due to metastatic disease at the time of presentation. An MIS approach was utilized in 47 (23.4%) of patients. Thus, there were 201 patients across 13 institutions included in this study. Within this group, there were 2 robotic ACC resections, 1 retroperitoneoscopic approach, 3 hand-assisted approaches, and 32 laparoscopic resections. In addition, 9 cases were included in the MIS group as an intention to treat analysis due to conversion from laparoscopic to open

surgery (19.0% conversion) (Figure 1). Thus, there were 38 patients in the non-converted MIS group, and 154 patients in the OA group.

There was no difference among participating institutions in the decision to proceed with a MIS approach to surgery ($p=0.24$). The gender distribution, BMI, and ASA classification were comparable between both approaches (Table 1). Utilization of an MIS approach was not associated with tumor laterality, functional tumor status, the era in which the operation was performed, or receipt of neoadjuvant chemotherapy. There were many differences between groups, with MIS patients presenting with smaller tumors (median size: 5.5 cm, MIS vs. 10.9 cm, OA; $p<0.001$), lower EBL (100 mL, MIS vs. 825 mL, OA; $p=0.002$), shorter length of stay (median LOS: 3 days, MIS vs. 6 days, OA; $p<0.001$), and lower pathologic T stage (75%, MIS vs. 44.3%, OA for T1-T2; $p<0.001$). A complete comparison of patient demographic, perioperative, and tumor data between MIS and OA are summarized in Table 1.

In the comparison of non-converted MIS versus OA, univariable analysis revealed smaller tumor size (median size: 5.5 cm, non-converted MIS vs. 10.9 cm, OA; $p<0.001$), lower EBL (100 mL, non-converted MIS vs. 825 mL, OA; $p=0.002$), shorter median operative time (156 minutes, non-converted MIS vs. 236 minutes, OA; $p=0.007$), shorter length of stay (2 days, non-converted MIS vs. 6 days, OA; $p=0.001$) and lower T stage (T1-2: 77.8%, non-converted MIS vs. 44.3%, OA; $p<0.001$) as statistically different in the MIS group.

Perioperative Morbidity and Mortality

There was no difference in 30-day or in-hospital mortality following adrenalectomy (Table 2). There was no difference in 30-day overall morbidity between MIS and open surgery groups ($p=0.839$). For patients who experienced post-operative complications, there were no differences in the grade of complication ($p=0.537$). There was no difference in the rate of intraoperative tumor rupture ($p=0.612$), or necessity for re-operation between groups ($p=0.871$). Of note, there were no differences between the overall morbidity ($p=0.669$), 30-day mortality ($p=0.563$) and in-hospital mortality ($p=0.587$) with the era in which the operation was performed. In the subgroup analysis of non-converted MIS cases compared to OA, there was no difference in the overall 30-day complication rate (25.0%, non-converted MIS vs. 30.9%, OA; $p=0.669$), low grade of complications (71.4%, non-converted MIS vs. 59.6%, OA; $p=0.694$), intraoperative tumor rupture (8.8%, non-converted MIS vs. 9.4%, OA; $p=0.999$), or R0 status (77.0%, non-converted MIS vs. 72.0%, OA; $p=0.50$).

Potential Influences on Resection Margin Status

The tumor size overlap between MIS (including converted cases) and OA cases ranged from 3.7 cm to 16 cm. On univariable analysis, the early surgical era was significantly associated with higher R1 status (37.5%, early era vs. 20.9%, late era; $p=0.017$). Of note, the approach ($p=0.953$), pre-operative tumor size ($p=0.661$), tumor size ($p=0.792$), and size-approach ($p=0.817$) were not associated with R1 status. No factors were significantly associated with an impact on R1 status in multivariable analysis (Table 3). Of note, there was no association of type of surgical approach with margin status.

Prognostic Indicators, Overall and Disease-Free Survival Following Resection of ACC

The surgical approach, tumor size, EBL (dL), length of stay, and T stage were included in univariable and multivariable analysis of potential prognostic indicators in OS and DFS. In our analysis, EBL and transfusion were correlated by Pearson coefficient ($R=0.660$), whereas EBL and tumor size were not ($R=0.273$), nor was T stage and tumor size ($p=0.331$). Hence only EBL was selected in the current analyses. On univariable analysis, significant prognostic factors for OS included tumor size ($p=0.026$), EBL ($p=0.002$), and T stage ($p=0.003$). EBL ($p=0.038$) and T stage ($p=0.045$) were independently predictive of OS on multivariable analysis (Table 4b). Similarly, tumor size ($p=0.043$) was significantly associated with DFS on univariable analysis, however there were no factors that were independently correlated with DFS on multivariable analysis (Table 4c). Of note, the era in which the operation was performed had no impact on OS ($p=0.809$) or on DFS ($p=0.151$).

There was no difference in median and 5-year OS between groups (MIS vs. OA: 91.0 months vs. 53.9 months, and 67.7% vs. 48.6%, respectively; $p=0.289$, Table 4a; Figure 2a). In addition, there was no difference in the median and 5-year DFS for patients who underwent MIS versus open surgery (14.3 months vs. 9.8 months, and 9.1% vs. 3.8% respectively ($p=0.174$, Table 4a; Figure 2b). Overall disease recurrence rates were comparable between both groups ($p=0.074$) (Table 2). On multivariable analysis, after controlling for tumor size, EBL, LOS, and T stage, there was no difference in OS and DFS rates associated with the type of surgical approach ($p=0.239$, and $p=0.285$, respectively) (Table 4b and 4c; Figure 2a and 2b, respectively). After adjusting for the approach and propensity score in multivariable logistic regression analyses, neither the propensity score nor surgical approach was predictive of OS or DFS (OS: propensity score $p=0.354$, approach $p=0.302$; DFS: propensity score $p=0.453$, approach $p=0.306$).

In subgroup analysis of non-converted MIS cases to OA, univariable analysis revealed EBL ($p=0.008$) and T Stage ($p=0.002$) as predictors for OS however, no factors were identified for DFS in this cohort. On multivariable analyses, EBL ($p=0.020$) was the only independent prognostic factor for OS, and no factors were identified for DFS. There were no differences in median and 5-year OS based on surgical approach (non-converted MIS vs. OA: 90.9 months vs. 53.9 months, and 68.9% vs. 48.6%; $p=0.261$). Similarly, there were no differences in the median and 5-year DFS between non-converted MIS and OA (18.8 months vs. 9.8 months, and 11.1% vs. 3.8%, respectively; $p=0.083$).

Predictors of Conversion to Open Surgery

Subgroup analyses of patients who underwent conversion to open surgery from a minimally-invasive approach were compared to cases completed using the MIS approach, (9 vs. 38 cases, respectively). On univariable analysis, the cases completed using MIS techniques had significantly lower BMI (median: 25.5 kg/m², range: 19.0 – 50.0, non-converted MIS vs. 34.0 kg/m², range: 25.4 – 64.0, converted MIS; $p=0.020$), smaller tumor size (median: 6.5 cm, range: 3.0 – 15.0, non-converted MIS vs. 11.0 cm, range: 7.0 – 15.0, converted MIS; $p<0.001$), lower EBL (median: 100 mL, range: 25 – 450, non-converted MIS vs. 800 mL, range: 400 – 1400, converted MIS; $p<0.001$) and shorter operative times (156 min, range: 79 – 318, non-converted MIS vs. 358 min, range: 205 – 780, converted MIS; $p=0.001$). After

adjusting for BMI, tumor size, EBL, and operative time on multivariable analysis, there was no difference in OS and DFS rates associated with the type of surgical approach ($p=0.540$ and $p=0.197$, respectively).

Discussion

This study represents one of the largest comparative series of the effect of type of surgical approach for ACC. To date, the current literature includes small case series, lacking power to perform adequate case matching [2-4,7,11-13,18,19] (Table 5). In this study, there was no difference in R0 status, tumor recurrence, intraoperative tumor rupture, or evidence of microvascular or capsular invasion between MIS and OA. Our findings highlighted EBL and T stage as independent prognostic indicators for OS, but not the surgical approach.

Therefore, in these highly selected patients, there was no difference in outcome when MIS techniques were utilized. Notably, there was no difference in overall morbidity or grade of complication. Potential explanations for this finding may be that morbidity is linked to the risk inherent with the need for *en bloc* resection or the absence of anastomoses that drives surgical complications for other tumor types. The exact reason for the lack of association with between surgical approach and complications is unclear and larger series are required to verify these results.

Our group previously identified independent associations between post-operative complications and decreased OS following resection of various tumors including ACC and gastric carcinoma [15,20]. Peritoneal carcinomatosis and laparoscopy have been anecdotally correlated, however our data do not reflect a difference in tumor recurrence between approaches. Earlier under-powered reports have cautioned against laparoscopic adrenalectomy for ACC due to high rates of peritoneal carcinomatosis attributed to violation of the tumor capsule during manipulation [6,13,21]. Although the development of peritoneal carcinomatosis was not studied in this series, our data did not reveal a greater risk of intraoperative tumor rupture within the MIS group, which likely reflects stringent patient selection, smaller tumor size, and increased proficiency of experienced MIS surgeons at participating institutions. Future studies will need to evaluate the presence of peritoneal carcinomatosis following MIS adrenalectomy in order to validate these results.

Our analysis reveals that the approach to surgery does not significantly affect the risk of margin positivity, which is consistent with prior analyses, although smaller tumors were more common in the MIS group [3,7,18]. In order to account for this difference, the size-approach variable, which accounted for the potential interactions of tumor size and approach in the same model, revealed no difference in margin status and tumor size. This is a critical finding, as the importance of achieving a margin-negative resection was reinforced in a large analysis of nearly 4,000 patients identified from the National Cancer Data Base, which revealed a clear improvement in survival among margin-negative patients, [9].

Prior authors have suggested relative contraindications to MIS adrenalectomy, such as prior laparotomy, trauma or widespread systemic disease [12,22]. However, others noted none of their laparoscopic cases were converted due to adhesions, even though as many as 69% of patients had undergone previous surgery [16]. Locally advanced disease, widespread

systemic disease, and tumor size greater than 10 cm have all been reported to favor the decision to pursue OA in other series [16,22-24]. The conversion rate in the current study was 19.1%. Other series have reported conversion rates ranging from 7 - 34.2%, however these data may also be obscured by small sample sizes and variations establishing comparative groups [19,25]. After analyzing the non-converted MIS cases compared to OA, there were no differences in terms of perioperative or survival outcomes. It is important to note that the diagnosis of ACC is often unknown to the surgeon prior to the operation and a significant proportion of adrenal lesions are resected under the premise of reasonable suspicion due to size and imaging characteristics. As a result, the decision to pursue an MIS or OA is chiefly guided by technical feasibility.

Stringent patient selection criteria have long been attributed to the success and safety of MIS adrenalectomy. The sole distinguishing preoperative criterion between the two approaches included smaller tumors in the MIS group. Not surprisingly, this suggests that size carries the greatest impact in decision-making regarding the surgical approach. Low stage tumors (AJCC T1 and T2) were independently predictive of improved survival. For ACC, the tumor, lymph node, and metastasis (TNM) classification proposed by the International Union Against Cancer (UICC) and the American Joint Commission on Cancer (AJCC), has been the most widely used classification and the staging strategy used in this study. However, TNM staging for ACC remains controversial in terms of true prognostic value. The European Network for the Study of Adrenal Tumors (ENSAT) is recognized for its ability to prognostically differentiate between stages II and III, and was validated in a large German ACC registry [26,27]. The Weiss score utilizes tumor pathology to assess prognosis, however is limited by its reliance on inter-rater reproducibility [28]. Although neither the ENSAT nor Weiss scoring classifications were available in this study, these staging systems offer additional prognostic insight to ACC survival analyses for future studies.

There are several limitations to this study. The retrospective design limited the analysis, and selection bias was likely. Retrospective data collection also contributed to missing data, which may have led to a misrepresentation of the impact of certain factors on MIS and OA. The limited recurrence data was likely the result of the referral-based practice among participating centers, wherein many patients are followed in the community and thus recurrence data was incomplete. In addition, this series was limited by the rarity of the disease, evidenced by the number of MIS cases available over a 20-year period (n=47). The diagnosis of ACC was not known prior to surgery. Therefore, the decision-making process for approach may have been driven by other factors, including clinical suspicion and tumor size, thus these data attest to the technical feasibility of MIS adrenalectomy. There remain inherent differences among centers that could not have been controlled, including protocols of perioperative management, oncologic follow-up, the impact of learning curve among trainees, and slight variations in surgical techniques. Under ideal circumstances, the most effective approach to confirm the findings in this study is a prospective, randomized controlled trial, but this is not realistic due to the rarity of ACC and the infrequency of pre-operative diagnosed ACC.

Despite these limitations, this study represents one of the largest series of MIS ACC resections treated curatively across 13 tertiary care centers in the country, offering a robust

illustration of current practice and long-term outcomes in an area of on-going clinical investigation. For suspected ACC, an open adrenalectomy is recommended in order to ensure a true oncologic resection particularly when there may be concern for invasion. However, an MIS approach may be utilized to patients with tumors ≤ 10 cm, providing the principles of an oncologic resection are followed.

Conclusion

In patients undergoing curative intent resection for ACC, MIS techniques offer comparable surgical and oncologic outcomes to open surgery among highly selected patients with a pre-operative tumor size less than or equal to 10.0 cm. There was no difference in OS or DFS based on the surgical approach. The deciding factor in the surgical approach for ACC must be driven by the ability to achieve a complete and appropriate oncologic resection. Open adrenalectomy should be utilized for adrenal masses with either preoperative or intraoperative evidence of local invasion or enlarged lymph nodes, regardless of size.

References

1. Gagner M, Lacroix A, Prinz RA, et al. Early experience with laparoscopic approach for adrenalectomy. *Surgery*. 1993; 114:1120–1124. discussion 1124–1125. [PubMed: 8256217]
2. Donatini G, Caiazzo R, Do Cao C, et al. Long-term survival after adrenalectomy for stage I/II adrenocortical carcinoma (ACC): a retrospective comparative cohort study of laparoscopic versus open approach. *Ann Surg Oncol*. 2014; 21:284–291. [PubMed: 24046101]
3. Fossa A, Rosok BI, Kazaryan AM, et al. Laparoscopic versus open surgery in stage I–III adrenocortical carcinoma -- a retrospective comparison of 32 patients. *Acta Oncol*. 2013; 52:1771–1777. [PubMed: 23398621]
4. Lombardi CP, Raffaelli M, De Crea C, et al. Open versus endoscopic adrenalectomy in the treatment of localized (stage I/II) adrenocortical carcinoma: results of a multiinstitutional Italian survey. *Surgery*. 2012; 152:1158–1164. [PubMed: 23068084]
5. Porpiglia F, Fiori C, Daffara F, et al. Retrospective evaluation of the outcome of open versus laparoscopic adrenalectomy for stage I and II adrenocortical cancer. *Eur Urol*. 2010; 57:873–878. [PubMed: 20137850]
6. Autorino R, Bove P, De Sio M, et al. Open Versus Laparoscopic Adrenalectomy for Adrenocortical Carcinoma: A Meta-analysis of Surgical and Oncological Outcomes. *Ann Surg Oncol*. 2016; 23:1195–1202. [PubMed: 26480850]
7. Miller BS, Gauger PG, Hammer GD, Doherty GM. Resection of adrenocortical carcinoma is less complete and local recurrence occurs sooner and more often after laparoscopic adrenalectomy than after open adrenalectomy. *Surgery*. 2012; 152:1150–1157. [PubMed: 23158185]
8. Ranvier GG, Inabnet WB 3rd. Surgical management of adrenocortical carcinoma. *Endocrinol Metab Clin North Am*. 2015; 44:435–452. [PubMed: 26038210]
9. Bilimoria KY, Shen WT, Elaraj D, et al. Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. *Cancer*. 2008; 113:3130–3136. [PubMed: 18973179]
10. Schteingart DE, Doherty GM, Gauger PG, et al. Management of patients with adrenal cancer: recommendations of an international consensus conference. *Endocr Relat Cancer*. 2005; 12:667–680. [PubMed: 16172199]
11. Mir MC, Klink JC, Guillotreau J, et al. Comparative outcomes of laparoscopic and open adrenalectomy for adrenocortical carcinoma: single, high-volume center experience. *Ann Surg Oncol*. 2013; 20:1456–1461. [PubMed: 23184291]
12. Cooper AB, Habra MA, Grubbs EG, et al. Does laparoscopic adrenalectomy jeopardize oncologic outcomes for patients with adrenocortical carcinoma? *Surg Endosc*. 2013; 27:4026–4032. [PubMed: 23765427]

13. Gonzalez RJ, Shapiro S, Sarlis N, et al. Laparoscopic resection of adrenal cortical carcinoma: a cautionary note. *Surgery*. 2005; 138:1078–1085. discussion 1085-1076. [PubMed: 16360394]
14. Moinzadeh A, Gill IS. Laparoscopic radical adrenalectomy for malignancy in 31 patients. *J Urol*. 2005; 173:519–525. [PubMed: 15643237]
15. Margonis GA, Amini N, Kim Y, et al. Incidence of Perioperative Complications Following Resection of Adrenocortical Carcinoma and Its Association with Long-Term Survival. *World J Surg*. 2016; 40:706–714. [PubMed: 26546184]
16. Cobb WS, Kercher KW, Sing RF, Heniford BT. Laparoscopic adrenalectomy for malignancy. *Am J Surg*. 2005; 189:405–411. [PubMed: 15820450]
17. Stefanidis D, Goldfarb M, Kercher KW, et al. SAGES guidelines for minimally invasive treatment of adrenal pathology. *Surg Endosc*. 2013; 27:3960–3980. [PubMed: 24018761]
18. Miller BS, Ammori JB, Gauger PG, et al. Laparoscopic resection is inappropriate in patients with known or suspected adrenocortical carcinoma. *World J Surg*. 2010; 34:1380–1385. [PubMed: 20372905]
19. Brix D, Allolio B, Fenske W, et al. Laparoscopic versus open adrenalectomy for adrenocortical carcinoma: surgical and oncologic outcome in 152 patients. *Eur Urol*. 2010; 58:609–615. [PubMed: 20580485]
20. Jin LX, Sanford DE, Squires MH 3rd, et al. Interaction of Postoperative Morbidity and Receipt of Adjuvant Therapy on Long-Term Survival After Resection for Gastric Adenocarcinoma: Results From the U.S. Gastric Cancer Collaborative. *Ann Surg Oncol*. 2016
21. Leboulleux S, Deandreis D, Al Ghuzlan A, et al. Adrenocortical carcinoma: is the surgical approach a risk factor of peritoneal carcinomatosis? *Eur J Endocrinol*. 2010; 162:1147–1153. [PubMed: 20348273]
22. Carnaille B. Adrenocortical carcinoma: which surgical approach? *Langenbecks Arch Surg*. 2012; 397:195–199. [PubMed: 21947510]
23. Sgourakis G, Lanitis S, Kouloura A, et al. Laparoscopic versus Open Adrenalectomy for Stage I/II Adrenocortical Carcinoma: Meta-Analysis of Outcomes. *J Invest Surg*. 2015; 28:145–152. [PubMed: 25536088]
24. Zini L, Porpiglia F, Fassnacht M. Contemporary Management of Adrenocortical Carcinoma. *European Urology*. 2011; 60:1055–1065. [PubMed: 21831516]
25. Kirshtein B, Yelle JD, Moloo H, Poulin E. Laparoscopic adrenalectomy for adrenal malignancy: a preliminary report comparing the short-term outcomes with open adrenalectomy. *J Laparoendosc Adv Surg Tech A*. 2008; 18:42–46. [PubMed: 18266573]
26. Fassnacht M, Johanssen S, Quinkler M, et al. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. *Cancer*. 2009; 115:243–250. [PubMed: 19025987]
27. Beuschlein F, Weigel J, Saeger W, et al. Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection. *J Clin Endocrinol Metab*. 2015; 100:841–849. [PubMed: 25559399]
28. Weiss LM. Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. *Am J Surg Pathol*. 1984; 8:163–169. [PubMed: 6703192]

Figure 1.
Patient selection criteria.

Figure 2a.

The 5-year overall survival for patients who underwent minimally invasive versus open resection for adrenocortical carcinoma. There was no difference in median and 5-year OS between groups (MIS vs. OA: 91.0 months vs. 53.9 months, and 67.7% vs. 48.6%, respectively; $p=0.239$. *Number at risk.

Figure 2b.

The 5-year disease-free survival for patients who underwent minimally invasive versus open resection for adrenocortical carcinoma. There was no difference in median and 5-year DFS for patients who underwent MIS versus OA (14.3 months vs. 9.8 months, and 9.1% vs. to 3.8% respectively, $p=0.285$). *Number at risk.

Table 1

Univariable Comparison of Demographic, Perioperative, and Histopathological Factors in Patients who Underwent Resection of Adrenocortical Carcinoma by Laparoscopic or Open Approaches to Surgery.

Factor	All Patients	N (%)		p-Value
		MIS Approach 47 (23.4)	Open Approach 154 (76.6)	
Demographics				
Age (years) (median – range)	198	53 (23-85)	51 (11-87)	0.151
Gender	201			0.105
Male		21 (44.7)	49 (31.8)	
Female		26 (55.3)	105 (68.2)	
BMI (kg/m ²) (median – range)	149	26 (19.0-64.0)	28 (19.0-69.0)	0.856
Perioperative Factors				
ASA Class	150			0.709
Low (I-II)		18 (51.4)	55 (47.8)	
High (III-IV)		17 (48.6)	60 (52.2)	
Preoperative Tumor Size (median – range)	196	5.5 (3.0-16.0)	10.9 (3.7-30.0)	<0.001*
Laterality				
Right	198	21 (45.7)	67 (44.1)	0.851
Left		25 (54.3)	85 (55.9)	
Functional Tumor Status	189	11 (25.0)	58 (40.0)	0.070
EBL (mL) (median – range)	135	100 (25-1400)	825 (100-15000)	0.002*
Median Operative Time (min)	114	180 (79-780)	236 (77-720)	0.121
Neoadjuvant Chemotherapy	190	0 (0)	2 (1.4)	0.435
Any Adjuvant Therapy	187	9 (21.4)	28 (19.3)	0.762
Adjuvant Mitotane	158	14 (37.8)	42 (34.7)	0.728
Adjuvant Radiation	161	5 (13.9)	10 (8.0)	0.284
Adjuvant Chemotherapy	187	5 (11.9)	20 (13.8)	0.752
LOS ^{\$} (days) (median – range)	164	3 (1.0-29.0)	6 (1.0-50.0)	<0.001*
Era (years)	190			0.186
Early (1994-2005)		10 (27.8)	61 (39.6)	
Late (2006-2014)		26 (72.2)	93 (60.4)	
Pathological Factors				
T Stage				
Low (T1-T2)	193	33 (75.0)	66 (44.3)	<0.001*
High (T3-T4)		11 (25.0)	83 (55.7)	
Positive Nodal Status	63	0 (0)	20 (33.9)	0.159
Lymphatic Invasion	132	13 (40.6)	52 (52.0)	0.263
Venous Invasion	75	2 (14.3)	29 (47.5)	0.023
Microvascular Invasion	120	14 (51.9)	57 (61.3)	0.380
Capsular Invasion	144	16 (48.5)	69 (62.2)	0.161

Factor	N (%)			p-Value
	All Patients	MIS Approach 47 (23.4)	Open Approach 154 (76.6)	
Positive Resection Margin	183	11 (27.5)	40 (28.0)	0.953

Bold values signify statistically significant factors $p < 0.05$.

Age and preoperative tumor size are depicted by the median.

^{\$}LOS: Length of Hospital Stay

* values denote factors included at the authors' discretion in multivariable Cox proportional hazards model, $p < 0.1$.

Table 2

Univariable Comparison of Postoperative Complications Following Resection of Adrenocortical carcinoma in Patients who Underwent Laparoscopic versus Open Surgery.

Factor	All patients	N (%)		p-Value
		MIS Approach	Open Approach	
In Hospital Mortality	183	0 (0)	5 (3.5)	0.216
30-day Mortality	189	1 (2.3)	3 (2.1)	0.934
30-day Complications	180	12 (29.3)	43 (30.9)	0.839
Clavien Grade	62			0.537
High (III-IV-V)		3 (30.0)	21 (40.4)	
Low (I-II)		7 (70.0)	31 (59.6)	
Abdominal Abscess	179	2 (5.0)	3 (2.2)	0.336
Pancreatic Leak	154	0 (0)	1 (0.8)	0.579
Pulmonary Embolism	179	1 (2.4)	5 (3.6)	0.711
Intraoperative Tumor Rupture	168	5 (12.2)	12 (9.4)	0.612
Postoperative Adrenal Insufficiency	174	7 (17.9)	32 (23.7)	0.448
Re-Operation	181	2 (4.9)	6 (4.3)	0.871
90-Day Re-Admission	164	3 (8.6)	19 (14.7)	0.343
Recurrence	173	22 (48.9)	82 (64.1)	0.074

Bold values signify statistically significant factors $p < 0.05$.

* values denote factors included at the authors' discretion in multivariable Cox proportional hazards model, $p < 0.1$.

Table 3

Univariable and Multivariable Analyses of Factors Influencing Resection Margin Status

Factor (N)	Resection Margin				
	Univariable		p-Value	Multivariable	
	R0 (%)	R1 (%)		HR (95% CI)	p-Value
Approach			0.953	NA	
MIS (40)	29 (72.5)	11 (27.5)			
OA (143)	103 (72.0)	40 (28.0)			
Size (cm) (median – range) (156)	10 (3.0-30.0)	9.9 (3.1-21.0)	0.661	NA	
Gender			0.589	NA	
Male (63)	47 (74.6)	16 (25.4)			
Female (120)	85 (70.8)	35 (29.2)			
Age (years) (180)	51.5 (11-85)	56 (14-87)	0.106	NA	
BMI (kg/m ²) (median – range) (138)	27 (19-64)	31.2 (19-69)	0.170	NA	
Era (years)			0.017 *		0.325
Early (1994-2005) (64)	40 (62.5)	24 (37.5)		1.680 [0.598 – 4.718]	
Late (2006-2014) (110)	87 (79.1)	23 (20.9)		Referent	
Tumor Size Category (cm)			0.792	NA	
1 (3.7 – 7.0 cm) (43)	32 (74.4)	11 (25.6)			
2 (7.1 – 10.0 cm) (38)	27 (71.1)	11 (28.9)			
3 (10.1 – 16.0 cm) (53)	41 (77.4)	12 (22.6)			
Size Approach (1/2/3-MIS/OA)			0.817 *		0.759
1-OA (24)	17 (70.8)	7 (29.2)		referent	
1-MIS (19)	15 (78.9)	4 (21.1)		0.615 [0.148 – 2.554]	0.503
2-OA (32)	22 (68.8)	10 (31.3)		1.137 [0.355 – 3.641]	0.829
2-MIS (6)	5 (83.3)	1 (16.7)		0.482 [0.047 – 4.962]	0.539
3-MIS (51)	40 (78.4)	11 (21.6)		NA	
3-OA (2)	1 (50.0)	1 (50.0)		NA	

MIS = minimally invasive surgery; OA = open adrenalectomy; R0 = negative resection margin; R1 = positive resection margin

Bolded values represent statistically significant predictive factors of R1 status, $p < 0.05$.* values denote factors included at the authors' discretion in multivariable Cox proportional hazards model, $p < 0.1$.

Table 4a

5-Year Overall and Disease Free Survival of all Patients who Underwent Resection of Adrenocortical Carcinoma

Factor	OS				DFS			
	Estimated 5- year OS	Median OS (months)	CI	p-Value	Estimated 5- year DFS	Median DFS (months)	CI	p-Value
MIS	67.7%	90.97	27.666-154.280	0.239	9.1%	14.26	0.856-27.662	0.285
Open	48.6%	53.88	28.546-79.216		3.8%	9.79	6.321-13.260	

DFS = disease free survival

OS = overall survival

Bold values signify statistically significant factors p<0.05.

Table 4b

Univariable and Multivariable Regression Analyses of Factors Influencing Overall Survival

Factor	OS			
	Univariable		Multivariable	
	HR (95% CI)	p-Value	HR (95% CI)	p-Value
Approach				
MIS	Referent	0.292	Referent	0.239
Open	1.141 [0.742-2.695]		2.152 [0.601-7.714]	
Size (cm)	1.048 [1.006-1.093]	0.026	0.989 [0.910-1.075]	0.795
EBL (dL)	1.016 [1.006-1.026]	0.002	1.013 [1.001-1.026]	0.038
Length of Stay (days)	1.016 [0.976-1.057]	0.439	0.978 [0.923-1.036]	0.452
T Stage				
(T1-T2)	Referent	0.003	Referent	0.045
(T3-T4)	2.129 [1.282-3.536]		2.102 [1.016-4.348]	

OS = overall survival

All factors included in a Cox proportional hazards model satisfied criteria of $p < 0.1$ .Bolded values represent statistically significant and independent predictive factors of OS, $p < 0.05$.

Table 4c

Univariable and Multivariable Regression Analyses of Factors Influencing Disease Free Survival

Factor	DFS			
	Univariable		Multivariable	
	HR (95% CI)	p-Value	HR (95% CI)	p-Value
Approach				
MIS	Referent	0.176	Referent	0.285
Open	1.407 [0.858-2.309]		0.582 [0.216-1.570]	
Size (cm)	1.035 [1.001-1.070]	0.043	1.017 [0.955-1.084]	0.598
EBL (dL)	1.007 [0.998-1.017]	0.138	1.008 [0.997-1.019]	0.162
Length of Stay (days)	1.009 [0.979-1.039]	0.577	0.994 [0.957-1.033]	0.374
T Stage				
(T1-T2)	Referent	0.087	Referent	0.605
(T3-T4)	1.439 [0.948-2.184]		1.171 [0.643-2.135]	

DFS = disease free survival

All factors included in a Cox proportional hazards model satisfied criteria of $p < 0.1$ .Bolded values represent statistically significant predictive factors of DFS, $p < 0.05$.

Table 5

Published Series Evaluating Outcomes Exclusively Following Resection of Adrenocortical Carcinoma

Author, Year	Institution	No. of ACC	No. of Cases Lap/Open	Overall Survival Lap/Open	p-Value
Donatini et al., 2014	Lille Regional University	34	13/21	85/81 %	0.63
Fossa et al., 2013	Oslo University Hospital	32	17/15	103/36 mo.	0.22
Mir et al., 2013	Cleveland Clinic	44	18/26	58/54 %	0.6
Cooper et al., 2013	Cleveland Clinic	46	46/46	54/110 mo.	0.07
Miller et al., 2012	University of Michigan	156	46/110	Stage II: 51/103 mo. Stage III: 28/44	0.002
Lombardi et al., 2012	Italian multi-institutional Study	156	30/126	66.5/47.5 %	0.77 0.20
Brix et al., 2010	German Adrenocortical Carcinoma Registry	152	35/117	ND	0.55
Miller et al., 2010	University of Michigan	88	17/71	NR	NR
Leboulleux et al., 2010	University Paris Sud-XI	64	5/58	5/38 mo.	NR
Porpiglia et al., 2010	University of Turin	43	18/25	95/72 %	NR
Gonzales et al., 2005	M.D. Anderson Cancer Center	136	6/133	33/43 mo.	NR

NR = not reported; ND = no difference, mo. = months